Chronic hepatitis B (CHB) is currently estimated to affect over 250 million people worldwide, and tenofovir disoproxil fumarate (TDF) is currently the most widely used antiviral agent for CHB ...

While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

Tenofovir disoproxil fumarate 40mg per 1g pwd. Test for HBV and HIV-1 infection prior to initiation. May use tabs or oral pwd (if unable to swallow). Mix oral pwd with 2–4oz of soft food not ...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

Chronic hepatitis B (CHB) poses a huge health care burden as it is a common cause of chronic liver disease and is also associated with the development of liver cirrhosis and liver cancer. The ...

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

The management of chronic hepatitis B (CHB) during pregnancy remains a challenge and involves various aspects of maternal-fetal care. Despite the standard immunoprophylaxis, a significant portion ...